424 related articles for article (PubMed ID: 12764576)
21. Characterization of the various functional pathways elicited by synthetic agonists or antagonists at the melatonin MT
Legros C; Dupré C; Brasseur C; Bonnaud A; Bruno O; Valour D; Shabajee P; Giganti A; Nosjean O; Kenakin TP; Boutin JA
Pharmacol Res Perspect; 2020 Feb; 8(1):e00539. PubMed ID: 31893123
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and pharmacological evaluation of 1,2,3,4-tetrahydropyrazino[1,2-a]indole and 2-[(phenylmethylamino)methyl]-1H-indole analogues as novel melatoninergic ligands.
Markl C; Attia MI; Julius J; Sethi S; Witt-Enderby PA; Zlotos DP
Bioorg Med Chem; 2009 Jul; 17(13):4583-94. PubMed ID: 19473848
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and pharmacological evaluation of dual ligands for melatonin (MT1/MT2) and serotonin 5-HT2C receptor subtypes (II).
Ettaoussi M; Pérès B; Errazani A; Boutin JA; Caignard DH; Delagrange P; Melnyk P; Berthelot P; Yous S
Eur J Med Chem; 2015 Jan; 90():822-33. PubMed ID: 25528336
[TBL] [Abstract][Full Text] [Related]
24. The influence od melatonin receptors antagonists, luzindole and 4-phenyl-2-propionamidotetralin (4-P-PDOT), on melatonin-dependent vasopressin and adrenocorticotropic hormone (ACTH) release from the rat hypothalamo-hypophysial system. In vitro and in vivo studies.
Juszczak M; Roszczyk M; Kowalczyk E; Stempniak B
J Physiol Pharmacol; 2014 Dec; 65(6):777-84. PubMed ID: 25554981
[TBL] [Abstract][Full Text] [Related]
25. XFEL structures of the human MT
Johansson LC; Stauch B; McCorvy JD; Han GW; Patel N; Huang XP; Batyuk A; Gati C; Slocum ST; Li C; Grandner JM; Hao S; Olsen RHJ; Tribo AR; Zaare S; Zhu L; Zatsepin NA; Weierstall U; Yous S; Stevens RC; Liu W; Roth BL; Katritch V; Cherezov V
Nature; 2019 May; 569(7755):289-292. PubMed ID: 31019305
[TBL] [Abstract][Full Text] [Related]
26. Melatonin receptors as therapeutic targets in the suprachiasmatic nucleus.
Pévet P
Expert Opin Ther Targets; 2016 Oct; 20(10):1209-18. PubMed ID: 27082492
[TBL] [Abstract][Full Text] [Related]
27. Ligand efficacy and potency at recombinant human MT2 melatonin receptors: evidence for agonist activity of some mt1-antagonists.
Nonno R; Pannacci M; Lucini V; Angeloni D; Fraschini F; Stankov BM
Br J Pharmacol; 1999 Jul; 127(5):1288-94. PubMed ID: 10455277
[TBL] [Abstract][Full Text] [Related]
28. Highly Potent and Selective MT2 Melatonin Receptor Full Agonists from Conformational Analysis of 1-Benzyl-2-acylaminomethyl-tetrahydroquinolines.
Spadoni G; Bedini A; Lucarini S; Mari M; Caignard DH; Boutin JA; Delagrange P; Lucini V; Scaglione F; Lodola A; Zanardi F; Pala D; Mor M; Rivara S
J Med Chem; 2015 Sep; 58(18):7512-25. PubMed ID: 26334942
[TBL] [Abstract][Full Text] [Related]
29. Gene structures, biochemical characterization and distribution of rat melatonin receptors.
Ishii H; Tanaka N; Kobayashi M; Kato M; Sakuma Y
J Physiol Sci; 2009 Jan; 59(1):37-47. PubMed ID: 19340560
[TBL] [Abstract][Full Text] [Related]
30. Strategies leading to MT2 selective melatonin receptor antagonists.
Spadoni G; Bedini A; Piersanti G; Mor M; Rivara S; Tarzia G
Adv Exp Med Biol; 2003; 527():577-85. PubMed ID: 15206776
[TBL] [Abstract][Full Text] [Related]
31. Gender-related invasion differences associated with mRNA expression levels of melatonin membrane receptors in colorectal cancer.
León J; Casado J; Carazo A; Sanjuán L; Maté A; Muñoz de Rueda P; de la Cueva P; Quiles R; Ruíz S; Ruíz-Extremera A; Salmerón J
Mol Carcinog; 2012 Aug; 51(8):608-18. PubMed ID: 21809392
[TBL] [Abstract][Full Text] [Related]
32. Microtubules modulate melatonin receptors involved in phase-shifting circadian activity rhythms: in vitro and in vivo evidence.
Jarzynka MJ; Passey DK; Johnson DA; Konduru NV; Fitz NF; Radio NM; Rasenick M; Benloucif S; Melan MA; Witt-Enderby PA
J Pineal Res; 2009 Mar; 46(2):161-71. PubMed ID: 19175856
[TBL] [Abstract][Full Text] [Related]
33. Synthesis of 5-substituted-2,3-dihydro-1,4-benzoxathiins: biological evaluation as melatonin receptors ligands.
Charton I; Suzenet F; Boutin JA; Audinot V; Delagrange P; Bennejean C; Renard P; Guillaumet G
J Enzyme Inhib Med Chem; 2003 Apr; 18(2):187-93. PubMed ID: 12943203
[TBL] [Abstract][Full Text] [Related]
34. Characterization of the Mel1c melatoninergic receptor in platypus (Ornithorhynchus anatinus).
Gautier C; Guenin SP; Riest-Fery I; Perry TJ; Legros C; Nosjean O; Simonneaux V; Grützner F; Boutin JA
PLoS One; 2018; 13(3):e0191904. PubMed ID: 29529033
[TBL] [Abstract][Full Text] [Related]
35. Industrial and academic approaches to the search for alternative melatonin receptor ligands: An historical survey.
Bedini A; Boutin JA; Legros C; Zlotos DP; Spadoni G
J Pineal Res; 2024 May; 76(4):e12953. PubMed ID: 38682544
[TBL] [Abstract][Full Text] [Related]
36. Investigational selective melatoninergic ligands for receptor subtype MT2.
Wan N; Zhang FF; Ju J; Liu DZ; Zhou SY; Zhang BL
Mini Rev Med Chem; 2013 Aug; 13(10):1462-74. PubMed ID: 23815579
[TBL] [Abstract][Full Text] [Related]
37. MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective.
Liu J; Clough SJ; Hutchinson AJ; Adamah-Biassi EB; Popovska-Gorevski M; Dubocovich ML
Annu Rev Pharmacol Toxicol; 2016; 56():361-83. PubMed ID: 26514204
[TBL] [Abstract][Full Text] [Related]
38. 2-Arylmelatonin analogues: Probing the 2-phenyl binding pocket of melatonin MT
Mari M; Elisi GM; Bedini A; Lucarini S; Retini M; Lucini V; Scaglione F; Vincenzi F; Varani K; Castelli R; Mor M; Rivara S; Spadoni G
Eur J Med Chem; 2022 Dec; 243():114762. PubMed ID: 36150258
[TBL] [Abstract][Full Text] [Related]
39. Homology models of melatonin receptors: challenges and recent advances.
Pala D; Lodola A; Bedini A; Spadoni G; Rivara S
Int J Mol Sci; 2013 Apr; 14(4):8093-121. PubMed ID: 23584026
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological characterization of M-II, the major human metabolite of ramelteon.
Nishiyama K; Nishikawa H; Kato K; Miyamoto M; Tsukamoto T; Hirai K
Pharmacology; 2014; 93(3-4):197-201. PubMed ID: 24923230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
